Search research articles
Contact Us
Filters
Showing results (31-40 of 77) with videos related to
Page
of 8
Sort By:
Nature Reviews. Clinical Oncology
|
April 7, 2011
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
Martin D Forster, Konstantin J Dedes, Shahneen Sandhu, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
January 22, 2014
Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit
Khurum Khan, Joo Ern Ang, Naureen Starling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2012
Toward a better dialogue between neuro-oncologists and phase I investigators
Christophe Massard, Shahneen Sandhu, Montserrat Blanco, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 4, 2018
The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials
Terri Patricia McVeigh, Raghav Sundar, Nikolaos Diamantis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 23, 2010
Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy
Liz Y Han, Vasilios Karavasilis, Tom van Hagen, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 26, 2017
Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?
Marta Capelan, Desamparados Roda, Elena Geuna, et al.
Drug Discovery Today
|
December 8, 2009
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
Craig P Carden, Debashis Sarker, Sophie Postel-Vinay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2011
Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials
David Olmos, Richard D Baird, Timothy A Yap, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 12, 2014
Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors
Robin L Jones, Edward S Kim, Pilar Nava-Parada, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 15, 2014
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey
Xavier Paoletti, Christophe Le Tourneau, Jaap Verweij, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 77) with videos related to
Sort By:
Page
of 8
Nature Reviews. Clinical Oncology
|
April 7, 2011
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
Martin D Forster, Konstantin J Dedes, Shahneen Sandhu, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
|
January 22, 2014
Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit
Khurum Khan, Joo Ern Ang, Naureen Starling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2012
Toward a better dialogue between neuro-oncologists and phase I investigators
Christophe Massard, Shahneen Sandhu, Montserrat Blanco, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 4, 2018
The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials
Terri Patricia McVeigh, Raghav Sundar, Nikolaos Diamantis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 23, 2010
Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy
Liz Y Han, Vasilios Karavasilis, Tom van Hagen, et al.
Lung Cancer (Amsterdam, Netherlands)
|
August 26, 2017
Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?
Marta Capelan, Desamparados Roda, Elena Geuna, et al.
Drug Discovery Today
|
December 8, 2009
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
Craig P Carden, Debashis Sarker, Sophie Postel-Vinay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 3, 2011
Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials
David Olmos, Richard D Baird, Timothy A Yap, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 12, 2014
Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors
Robin L Jones, Edward S Kim, Pilar Nava-Parada, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 15, 2014
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey
Xavier Paoletti, Christophe Le Tourneau, Jaap Verweij, et al.
Page
of 8